PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me

What FDA’s register states

FDA register entry for Apothecary Pharma, LLC
FieldWhat FDA’s record statesSource
FacilityApothecary Pharma, LLCFDA register
LocationCary, NCFDA register
First registeredSep 7, 2024FDA register
Most recent registrationOct 21, 2026FDA register
Last FDA inspectionSep 2, 2026FDA register
Form 483 issuedYesFDA register
Recall conductedNoFDA register
Action based on last inspectionOpenFDA register
Earlier compounding actionFDA notes at least one previous compounding inspection that resulted in a Form 483, warning letter or other actionFDA register
Intends to compound sterile drugs from bulkYesFDA register

Registration is a filing, not an approval. A Form FDA 483 lists what investigators observed; in FDA’s words it “does not constitute a final agency determination of whether any condition is in violation of the FD&C Act or any relevant regulations.” “Open” means FDA has not determined whether further action will be taken.

GLP-1 warning letters to a firm of this name

Matched by name; FDA’s letter gives the address it was sent to.

GLP-1 recalls by a firm of this name

  • Class II, ongoing, reported Oct 14, 2026Lack of Assurance of SterilityD-0036-2027 · Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC...

Matched by name, from FDA’s enforcement reports (updated by FDA Nov 11, 2026). Every GLP-1 recall

Source

Copied from FDA’s Registered Outsourcing Facilities table ↗, updated by FDA Nov 17, 2026, read Nov 18, 2026. The table does not include State Board of Pharmacy actions. All 100 registered facilities